Cite

    Faber, E. et al. (n.d.). A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leukemia & lymphoma. 57 (2), pp. 370-375. [Online].